GRTX — Galera Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.81m
- $144.57m
Annual cashflow statement for Galera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -74.2 | -80.5 | -62.2 | -59.1 | -19 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 10.4 | 14.4 | 15.5 | 20.1 | 8.24 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.91 | -2.63 | 3.26 | -6.17 | -1.25 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -59.5 | -68 | -43.4 | -44.8 | -12.1 |
| Capital Expenditures | -0.457 | -0.283 | -0.025 | -0.059 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 37 | 5.52 | 24 | 27.4 | -0.046 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 36.5 | 5.24 | 24 | 27.3 | -0.046 |
| Financing Cash Flow Items | — | — | — | 2.01 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 20.5 | 66.7 | 3.89 | 31.5 | 2.22 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.48 | 3.99 | -15.5 | 13.9 | -9.97 |